good quarter businesses. which growth afternoon. results, American you, We're with pleased XXXX fiscal another North quarter and solid our across with third Thank momentum, reflect of Brian, our
against exceeded our to and results demonstrating expectations, for ability execute priorities create company long-term consistently Our shareholders. sustainable our value
for U.S. consolidated segment. petition I October to Pharmaceutical recorded an $XXX to to results, of million item our highlight provision third sales is trade from provision after want This Aid million our debt I in impacted results. within to accounts $XXX filing. its bankruptcy Rite turn GAAP-only prior one for GAAP of bad receivable that uncollected XXXX, the tax, additional or Before We quarter pretax
over we interim an through operational We a adjusted to provide the XX fiscal our continue material on closely Rite Rite will efficiency fiscal share of diluted as XXXX Aid's refer bankruptcy developments. impact not providing Aid will monitoring results. XXXX distribution comments earnings adjusted for same years. excellence and The to our services results. my We're agreement, to distribution remainder per have have
and review quarter. growth in biopharma our sustained U.S. including investments underscores McKesson services. This third oncology strong operating quarter, portfolio, Solutions Prescription and by with start Let solid performance led across in the Pharmaceutical delivered of me a fiscal the growth diversified year-over-year the differentiated third in Technology execution segments. and
our confidence full-year $XX.XX in performance the of for fiscal a outlook result earnings of operating diluted XXXX a narrowing to business, we're per As the $XX.XX. share third and range new our adjusted to increasing quarter and
trends, move including segment, retail lower our partially billion, from segment, led divestitures customers utilization and strong medications, by increased U.S. GLP-X account to offset growth Let XXXX in volumes McKesson's by business. from International fiscal $XX.X within to continued the revenues in the specialty Revenues me products, Pharmaceutical European resulting XX% national higher consolidated results.
our gross fiscal Gross an operations, $X.X impact of of quarter, X%. COVID-XX from Excluding operations, impact the of our business European profit the excluding programs increase European increased increased including completed divestitures, in revenues the the completed billion and divestitures, profit impact government the including XXXX, XX%. XX%. for When U.S. business was
due higher and Prescription impact growth divestitures, the increased excluding Technology U.S. When completed the expenses expenses Solutions increased the X% in the operations, quarter to our Operating including support of European to costs Pharmaceutical segments. year-over-year. X% business in operating
or termination to pretax million TRA, Healthcare. agreement, a Third XXXX of profit related the Fiscal operating results with tax billion. included X% $X.X benefit Change early decreased quarter receivable to the of $XXX
our also the Technology government COVID-XX from These impacted Year-over-year million in charge distribution in segment. U.S. were nonrecurring offset U.S. by growth mitigated and Prescription by items by a COVID-XX Pharmaceutical $XX lower segment. and contributions partially were anticipated programs, results which Solutions Pharmaceutical contributions were U.S. commercial from
operating from and gains profit XXXX increased equity for fiscal the associated TRA XXXX, investments or $XXX items, McKesson fiscal When in million the adjusting in and $X.XX these early Ventures X% benefit including XXXX of losses quarter. the in termination and with
Moving recognition was for by loan resulting line, a the expense decrease of tax interest was year-over-year, the below XX% portfolio. $XX of XX.X%, of from The quarter the our million, the management rate driven tax quarter. discrete benefit in effective effective
our of discrete As of tax driven effective by our tax reminder, items. can income timing a vary mix the rate and quarter-to-quarter,
Third XX% over the a quarter was share quarter $X.XX, diluted weighted year-over-year. average Consolidated shares an X% was decrease prior of per year. diluted million, of which third represents outstanding earnings XXX.X increase
fiscal the COVID-XX includes a and TRA Pharmaceutical increased in of related impacts commercial charge nonrecurring the segment in program in U.S. and $X.XX distribution increase vaccine U.S. XXXX. benefit government XXXX from of $X.XX the the This to termination fiscal our COVID-XX approximately the and
Slide results, which X U.S. segment Turning be can quarter on through XX, to with Pharmaceutical. and found third starting our
product we and pace medications quarter, year. volume to faster the continue and grow customer channels. the all Specialty GLP-X increases compared prior pharmaceuticals a categories at across During experienced to
prescription and of increased Third higher XX% year-over-year, increase specialty driven quarter retail GLP-X billion, by medications. revenues volumes volumes, account were customers products, from $XX national an including
XXXX. In increase compared billion, billion of were GLP-X $X.X XX%, the fiscal revenues or $X.X quarter, approximately an to
fiscal peaked fourth anticipate and During we our contributions COVID-XX significantly distribution do material commercial noted December. vaccine from from vaccine also We increased distribution. October, in contributions quarter. commercial fiscal not COVID-XX in commercial the vaccine November third quarter, in In quarter, COVID-XX distribution our declined then
XXXX operating operating segment, U.S. the fiscal growth in distribution distribution of products distribution and increased for Adjusting XXXX by and delivered $XXX year-over-year. the the $XX profit COVID-XX COVID-XX providers in million of to nonrecurring the driven in systems. government fiscal impact growth third the X% commercial profit of the For quarter, million, to Pharmaceutical and charge specialty U.S. in X% vaccine health
GLP-X authorization of demand brand growth the segment, Solutions for increased Technology Prescription our access new In launches to and services. such our solutions, as medications led prior
For million. the increased profit revenues to year-over-year and $X.X $XXX XX% third quarter, X% increased operating to billion,
higher drove demand transaction Third increased our results volumes, in for our quarter logistics access and prior third-party prescription principally services business. reflect authorization which solutions, growth
new authorization increased services, of programs In sales the by access was across solutions. also and supported and strength to our to year-over-year growth affordability addition prior customers
were quarter, primary Turning in contributions care the billion X%, supplies to and program, growth in for and ancillary in the by the distribution the of vaccine businesses, $X anticipated Solutions. compared U.S. lower prior storage care driven year. kitting, by extended Revenues Medical-Surgical an the primarily COVID-XX partially increase to government's of offset
compared the was primary an dynamics, on a testing, visits illness third for including the to care vaccine basis. increased to In higher in modestly The quarter, year. headwind care vaccinations distribution sites patient operating profit compared expectations. also that across COVID-XX to the when moderately Demand alternate prior commercialized season we serve, the sequential be prior of continue overall quarter and
is various season the that year. during unique, on illnesses particular each illness severity a As respiratory and depending of onset reminder,
decrease Operating contributions U.S. vaccine the fiscal supplies season by ancillary and government's driven from million, COVID-XX a lower anticipated XX%, kitting, and profit distribution was compared XXXX. for to a softer storage of illness as of program $XXX the
the X%, the XXXX, in by growth extended delivered fiscal the segment items profit care impact driven businesses. of third and of growth primary excluding from care When quarter of the COVID-XX-related operating
European XX%, within me higher decrease by quarter $X.X let divestitures in Operating divestitures million, pharmaceutical business, was McKesson's International Next, by the Revenues third a driven billion, address distribution year-over-year, European partially in of Canada. decrease business. McKesson's by our offset with profit $XXX XX% the results. volumes of a driven were
$X to individual our review, segment related were quarter, influenced Corporate consolidated each financials or losses up per quarter-to-quarter. $XXX on in share, McKesson McKesson impact can investment Ventures within of the the Ventures which million performance expenses million be investments included $X.XX Wrapping equity of by the portfolio.
McKesson's results and that for and result, We resulted vary we're investments of the which obtaining pleased each this through the insights timing magnitude a gains investment. with the in remain been As has portfolio. can losses, and
from Excluding Ventures McKesson agreement our receivable quarter third and of the within portfolio fiscal X% tax termination in XXXX, the expenses the early XXXX gains fiscal and the decreased and Corporate benefit in XXXX in year-over-year. losses
cash to XX. cash capital $X.X be cash third the $X million which for found in quarter We can Slide with on ended XX in months. equivalents. and delivered now flow free billion flows and the and billion deployment, Turning $XXX We quarter cash the of trailing
$XXX Rite Third quarter free debts. cash and October provision Aid flow was impacted million bankruptcy for bad in by associated its the
be a of a resulting day our quarter-to-quarter. vary and metrics cash As timing, can impacted from reminder, the on position, capital quarter working by includes and week that cash flows the ends can each therefore, which
which support X new and first $XXX to made distribution in data of we of the existing centers, technology, the expenditure as fiscal priorities. capital months as analytics well During million, included our year, growth investments investments and
and to share Year-to-date, $X.X dividend repurchases shareholders, we of million billion returned $X.X cash in payments. of which billion $XXX included
Now to XXXX our turn fiscal updated let outlook. me
following list guidance on our provide our XX do we an Slides of not on full a found metrics can forward-looking basis. GAAP adjusted provided on non-GAAP through be in slide XX As supplemental A presentation. a are reminder, assumptions basis. The
with for start me our segments. XXXX fiscal the outlook Let
For Pharmaceutical year, the XX% and operating to year-over-year. to U.S. increase to now full to X% revenues we anticipate increase profit X% XX%
accounts And the impact XXXX, third XXXX, commercial Excluding of nonrecurring the X% U.S. the million increase third quarter growth. COVID-XX XX%. distribution XX% elevated of operating fiscal fiscal approximately segment COVID-XX to the anticipate profit charge, government of in net vaccine to for also we for the $XX of of distribution in in impact quarter
in that continued medication quarter. trends. GLP-X by Revenue growth the of and are margins specialty the to operating profit strong segment medications year-over-year continue will rate volumes in growth. quarter to although stable supported be robust, distribution, fourth headwind assumes These represent incorporates performance updated The growth and our will a growth moderate utilization third revenue outlook lower fiscal
dual deliver scaled and with mandate operating continues be our full-year we strength on Our oncology to to pleased and cost of product also broad the continue availability. the platform. which Generics program, reflects our profit growth And of lower leading
into Brian addition X Tennessee This mentioned, with practices. the of quarter, expanded we as
these organic With now oncology additions providers. growth, has U.S. X,XXX over and
segment, In volumes profit quarter growth strong operating higher X% solutions. growth organic reflecting Technology increased to continued Prescription to third anticipate we've across Solutions the growth XX%, we transaction revenue our of outlook to the and and performance, XX% access affordability and XX%,
The quarter-to-quarter of fiscal support size the timing variability prescription by and we that the in new drug our our fourth product product to trajectory investments timing, provide occur programs expand and this driven annual transaction segment for of in launches, is and verification and that volumes, our the and quarter. customers, portfolio pace
segment continues When anticipate alternate We items the we to all sites to to fiscal revenues XX%. of Solutions of Medical-Surgical XX% to operating year-over-year. to and a growth increase impact decrease X% operating X% to Our COVID-XX-related flat across XXXX the leader anticipate excluding X% approximately be profit to care. profit be from results,
modest updated that the earlier, third I which discussed primary reflect outlook improvement a sequential quarter results traffic. care in Our incorporates
to Ventures months losses includes recorded $XXX we associated International Finally, the XX% profit million, McKesson by million fiscal be which and support segment, by to range revenues X XX% to closed in In XXXX. the equity operating during $XXX decline growth spend the business. the to within business European with in that the to expenses and decline segment, McKesson's we anticipate XX% of of Corporate XX%, to year our investments the elevated reflecting to of anticipate divestitures in first technology
million. we effective We $XXX guidance. be income to in tax provide to Moving $XXX to to is and anticipate $XXX The do range noncontrolling change therefore, $XXX be rate quarterly to below not the line, we tax interest million XX%. approximately anticipate the to interest attributable tax million rate to predict, expense difficult of million approximately timing discrete year item XX% no effective to of and full of the
approximately free to cash flow $X.X Turning deployment. cash of anticipate now billion billion. and capital $X.X flow to We
Our quarter. from metrics will day including working marks quarter-to-quarter, of the the cash capital of the week that and the flow vary resulting impacted by free timing, close
incorporates the impact of Rite also outlook bankruptcy. October Our Aid the
$X Our shares. guidance of reflects plans to $X.X to billion repurchase approximately billion
a weighted of to repurchase the million. shares be XXX we approximately average activity, the diluted result estimate range in of As share outstanding
up Wrapping XXXX fiscal guidance.
narrowing we As new performance will a of to momentum share quarter moving the anticipate forward, in our X% growth year. combined XXXX and for fiscal solid and to range third outlook a XXXX, to decline profit result X% earnings confidence of fiscal increasing the $XX.XX per prior of are with diluted operating We our be to a compared $XX.XX.
to Excluding year-over-year, by long-term XX% target we certain items, increase above approximately operating X% profit anticipate to the range.
include certain U.S. losses in of XXXX related U.S. the Pharmaceutical in $X.XX tests program equity to fiscal COVID-XX and the As in associated Ventures fiscal Surgical COVID-XX Healthcare receivable with McKesson Change following: termination XXXX. and agreement related gains with a investments reminder, Medical a and items tax government XXXX the $X.XX and our segments, fiscal benefit early to XXXX and
increase outlook for XX%, indicates items. to share of growth diluted per earnings when The excluding our XX% to adjusted these certain
fiscal some the several Before The I we've momentum to business to share I'd XXXX. in past over expected fiscal years is close, our across thoughts on like XXXX. continue initial seen
and Solutions be previously more performance. demonstrating positions leading We segments market anticipate provided targets these for and our U.S. stable segments, financial we've to closely aligned Pharmaceutical long-term the growth will that Medical-Surgical
joint U.S. lead growth, Technology of Cannon Institute. confident that target. the in we're will supported our remain and business distribution X% Solutions growth the core our and Research Pharmaceutical, long-term by top solution U.S. anticipate our long-term above in X% to Network, sustainable the we to the with venture target at Oncology slightly Ontada seeing In Prescription Sarah the in We the set across end platform, oncology momentum or strength across
that As Solutions site across the believe to leader is site the as alternate settings. alternate continues the care the in well segment we market, Medical-Surgical positioned move
site channel years ahead. in enable us to the Our of and markets the setting alternate relationships every growth capture experience and the our in opportunity
expand to We the target growth, growth driven Solutions perform by higher-margin anticipate biopharma organic XX%, segment platform. that the our modestly of Technology may services XX% Prescription above we as long-term
International And Europe. Canadian XX of growth XXXX, operations the we the in countries business we we the that segment, operated fiscal For our in in anticipate divestitures XX continued operations. throughout completed of
exit we European As a the And of only of to not an exit. sell. completion part our intend Norway that as Norway entered the country reminder, agreement have remains we to into
we the on continue in business to Finally, will invest multiple materially fronts.
across investments our We the in positions. These pace services will product differentiated market-leading capabilities oncology enhancements and of and biopharma further cadence investment sustain our will development platforms. and and
will data will capabilities. capabilities also in our intelligence. and These and artificial unlocking acceleration invest and investments in in to to potential continue deliver And AI capacity, customer as adding several North investments excellence analytics, to automation distribution invest including American foundational footprint. enhancements. continue include to we We capacity We see regulatory increased the the of and
forecast we're several AI chain intake Although predictions, fraud including improve in use and clinical patient using to detection. accuracy the supply automatic throughout the stages, and cases, note generation, early productivity and disruption including supply algorithms system, improve workflow, chain
the stages implementation, investment we're our we're in and positions extend our AI early committed partners further development increased to our and leadership value deliver to and stakeholders. to Although of
business. Q&A against optimistic let's results successfully fiscal XXXX is fundamentals session. sustainable to sum pleased in growth we remain continue strong underlying drive positioned for with see framework and with We're and well to stakeholders. To we we financial about our stability our move all performance, strategic strength deliver to to outlook. of McKesson up, the the and as our strong that, long-term executed And the
